A Phase 1/2 interventional study of Chemotherapy and precision cells in Precision Cells, Chemotherapy and Advanced Lung Cancer, sponsored by Shanghai International Medical Center. Status unknown at 1 site in China. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2016-09-02.
Sponsored by Shanghai International Medical Center · Phase 1/2, Interventional, and Treatment
Objectives:
To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer.
Eligibility:
Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Lung Cancer.
A total of 40 patients may be enrolled over a period of 1-2 years.
1,391 studies on the registry are indexed under Liver Neoplasms; 345 are open to participants now.
This study's planned enrollment of 40 is below the median of 47 across 968 interventional studies indexed under Liver Neoplasms.
Browse Liver Neoplasms studies →Shanghai International Medical Center is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
precision cells combined with Chemotherapy treatment: Chemotherapy: once a week with a total of six times before 60 days prior to the start of drawing blood. precision cells：once per 3 weeks with a total of three periods.
Drug: Chemotherapy · Biological: precision cells
Once a week with a total of six times before 60 days prior to the start of drawing blood.
Drug: Chemotherapy
Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
precision cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Overall survival
Time frame: 2 years
Progress-free survival
Time frame: 2 years
Quality of life
Questionnaire will be used.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai International Medical Center